Heartflow Inc (HTFL) valuation
Heartflow P/E ratio history
Heartflow trades at 19.4 times its earnings over the last twelve months.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $29.15 | -$3.17 | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Heartflow valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| HeartflowHTFL | $5.09B | 19.4 | — | 24.0 |
| Merit Medical SystemsMMSI | $5.15B | 32.3 | 18.9 | 3.2 |
| Concentra Group Holdings Parent InCON | $5.17B | 26.1 | 23.1 | 2.3 |
| Ptc TherapeuticsPTCT | $5.00B | — | 27.8 | 4.3 |
| Mirum PharmaceuticalsMIRM | $5.18B | — | — | 8.4 |
| Option Care HealthOPCH | $5.00B | 24.1 | 16.1 | 0.9 |
| Lifestance Health GroupLFST | $5.20B | 103.3 | 33.9 | 3.3 |
| Crispr Therapeutics AgCRSP | $4.96B | — | — | 370.3 |
| Scholar Rock HoldingSRRK | $5.26B | — | — | — |
| Peer median | 29.2 | 23.1 | 3.3 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: HTFL financials · HTFL returns
No forecast, no recommendation. This page describes Heartflow Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.